|
US6022683A
(en)
*
|
1996-12-16 |
2000-02-08 |
Nova Molecular Inc. |
Methods for assessing the prognosis of a patient with a neurodegenerative disease
|
|
US6441149B1
(en)
|
1998-06-15 |
2002-08-27 |
Mitokor |
Diagnostic method based on quantification of extramitochondrial DNA
|
|
US6489095B2
(en)
|
1998-06-15 |
2002-12-03 |
Mitokor |
Diagnostic method based on quantification of extramitochondrial DNA
|
|
US6218117B1
(en)
|
1998-06-15 |
2001-04-17 |
Mitokor |
Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios
|
|
CA2330829C
(en)
|
1998-06-16 |
2011-08-02 |
Variagenics, Inc. |
Methods for treating a neurological disease by determining bche genotype
|
|
JP2002526124A
(ja)
|
1998-10-01 |
2002-08-20 |
ノヴァ モレキュラー インク． |
変異型ｇｐｉｉｉａ対立遺伝子および／または変異型ｇｐｉｉｂ対立遺伝子の存在を決定することにより、神経系疾患のリスクを有する対象を治療又は同定する方法
|
|
AU773329B2
(en)
*
|
1999-05-14 |
2004-05-20 |
Proteomedica Ab |
Materials and methods relating to disease diagnosis
|
|
JP2003521024A
(ja)
*
|
1999-06-25 |
2003-07-08 |
ジェネサンス・ファーマシューティカルズ・インコーポレーテッド |
ハプロタイプデータの入手および使用のための方法
|
|
US7058517B1
(en)
|
1999-06-25 |
2006-06-06 |
Genaissance Pharmaceuticals, Inc. |
Methods for obtaining and using haplotype data
|
|
US6692916B2
(en)
*
|
1999-06-28 |
2004-02-17 |
Source Precision Medicine, Inc. |
Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
|
|
US6960439B2
(en)
*
|
1999-06-28 |
2005-11-01 |
Source Precision Medicine, Inc. |
Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
|
|
US6573049B1
(en)
|
1999-07-26 |
2003-06-03 |
Nuvelo, Inc. |
Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
|
|
US6896881B1
(en)
|
1999-09-24 |
2005-05-24 |
Mayo Foundation For Medical Education And Research |
Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
|
|
AU2001240820A1
(en)
*
|
2000-03-15 |
2001-09-24 |
Oxford Glycosciences (Uk) Ltd. |
Proteins, genes and their use for diagnosis and treatment of vascular dementia
|
|
US20070179197A1
(en)
*
|
2000-05-01 |
2007-08-02 |
Accera, Inc. |
Compositions and methods for improving or preserving brain function
|
|
WO2007115282A2
(en)
*
|
2006-04-03 |
2007-10-11 |
Accera, Inc. |
Use of ketogenic compounds for treatment of age-associated memory impairment
|
|
AU2001257451A1
(en)
|
2000-05-01 |
2001-11-12 |
Accera, Inc. |
Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
|
|
US6835750B1
(en)
|
2000-05-01 |
2004-12-28 |
Accera, Inc. |
Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
|
|
US20080009467A1
(en)
*
|
2000-05-01 |
2008-01-10 |
Accera, Inc. |
Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
|
|
US6931326B1
(en)
|
2000-06-26 |
2005-08-16 |
Genaissance Pharmaceuticals, Inc. |
Methods for obtaining and using haplotype data
|
|
US20030105082A1
(en)
*
|
2001-12-03 |
2003-06-05 |
Murphy Greer Marechal |
Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
|
|
US20040106124A1
(en)
*
|
2001-02-12 |
2004-06-03 |
Murphy Greer M. |
Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
|
|
US6399310B1
(en)
|
2001-02-12 |
2002-06-04 |
Akzo Nobel N.V. |
Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
|
|
GB0106051D0
(en)
*
|
2001-03-12 |
2001-05-02 |
Isis Innovation |
Diagnostic screens for alzheimer's disease
|
|
US20030104453A1
(en)
*
|
2001-11-06 |
2003-06-05 |
David Pickar |
System for pharmacogenetics of adverse drug events
|
|
CN1612936A
(zh)
*
|
2001-11-09 |
2005-05-04 |
苏尔斯精细医药公司 |
利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
|
|
US20030224446A1
(en)
*
|
2001-12-20 |
2003-12-04 |
Harry G. Jean |
Method of predicting cytokine response to tissue injury
|
|
US20040267458A1
(en)
*
|
2001-12-21 |
2004-12-30 |
Judson Richard S. |
Methods for obtaining and using haplotype data
|
|
WO2003069431A2
(en)
*
|
2002-02-14 |
2003-08-21 |
Medavante, Inc. |
System and method for facilitating candidate and subject participation in clinical trial studies
|
|
US7432355B2
(en)
*
|
2002-08-09 |
2008-10-07 |
The J. David Gladstone Institutes |
Apolipoprotein E stable folding intermediate and methods of use thereof
|
|
US8688385B2
(en)
|
2003-02-20 |
2014-04-01 |
Mayo Foundation For Medical Education And Research |
Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
|
|
CA2525517C
(en)
*
|
2003-06-19 |
2016-05-31 |
Applied Research Systems Ars Holding N.V. |
Use of prion conversion modulating agents
|
|
US20050038692A1
(en)
*
|
2003-08-14 |
2005-02-17 |
Kane John Michael |
System and method for facilitating centralized candidate selection and monitoring subject participation in clinical trial studies
|
|
WO2005073892A2
(en)
*
|
2004-01-16 |
2005-08-11 |
Disease Management Services, Plc |
Disease management system
|
|
WO2006008119A1
(en)
|
2004-07-16 |
2006-01-26 |
Proteosys Ag |
Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases
|
|
US20060252775A1
(en)
*
|
2005-05-03 |
2006-11-09 |
Henderson Samuel T |
Methods for reducing levels of disease associated proteins
|
|
WO2007001883A2
(en)
*
|
2005-06-20 |
2007-01-04 |
Accera, Inc. |
Method to reduce oxidative damage and improve mitochondrial efficiency
|
|
EP3703058A1
(en)
*
|
2005-11-29 |
2020-09-02 |
Children's Hospital Medical Center |
A method of selecting a medication for a patient
|
|
US20080126118A1
(en)
*
|
2006-11-24 |
2008-05-29 |
General Electric Company, A New York Corporation |
Systems, methods and apparatus for a network application framework system
|
|
TWI362012B
(en)
*
|
2007-07-23 |
2012-04-11 |
|
System of providing hygienic education information and method thereof
|
|
CA2853992C
(en)
|
2007-07-31 |
2020-06-23 |
Cerecin Inc. |
Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
|
|
US20090198504A1
(en)
*
|
2008-02-05 |
2009-08-06 |
Medavante, Inc. |
Rater resource allocation systems and methods
|
|
US8105809B2
(en)
*
|
2008-07-03 |
2012-01-31 |
Accera, Inc. |
Enzymatic synthesis of acetoacetate esters and derivatives
|
|
AU2009266869B2
(en)
*
|
2008-07-03 |
2016-07-07 |
Cerecin Inc. |
Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
|
|
WO2010081825A2
(en)
|
2009-01-13 |
2010-07-22 |
Proteosys Ag |
Pirenzepine as an agent in cancer treatment
|
|
EP2360280A1
(en)
*
|
2010-02-24 |
2011-08-24 |
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol |
Genetic marker for the diagnosis of dementia with Lewy bodies
|
|
US20120078521A1
(en)
*
|
2010-09-27 |
2012-03-29 |
General Electric Company |
Apparatus, system and methods for assessing drug efficacy using holistic analysis and visualization of pharmacological data
|
|
US20130080182A1
(en)
*
|
2011-09-26 |
2013-03-28 |
Athleticode Inc. |
Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury
|
|
RU2467680C1
(ru)
*
|
2011-10-04 |
2012-11-27 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации |
Способ прогнозирования эффективности лечения больных ишемическим инсультом
|
|
US10658073B2
(en)
|
2014-08-15 |
2020-05-19 |
QIAGEN Redwood City, Inc. |
Methods and systems for interpretation and reporting of sequence-based genetic tests using pooled allele statistics
|
|
US10665328B2
(en)
|
2014-06-30 |
2020-05-26 |
QIAGEN Redwood City, Inc. |
Methods and systems for interpretation and reporting of sequence-based genetic tests
|
|
EP3628315A1
(en)
|
2018-09-28 |
2020-04-01 |
Université de Caen Normandie |
Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
|
|
WO2020091375A2
(ko)
*
|
2018-10-29 |
2020-05-07 |
고려대학교 산학협력단 |
항우울제 추천 방법 및 시스템
|